Full-Time

Associate Director

Multiple Teams

Posted on 5/9/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$147.1k - $197.1k/yr

+ Annual Bonus + Incentive Compensation Plan + Equity Awards

Remote in USA

Remote

Category
Medical, Clinical & Veterinary (1)
Requirements
  • PhD or MD/PhD in a relevant scientific discipline, with 4+ years’ experience in pharmaceutical or biotechnology settings, focusing on biomarker science in oncology.
  • Deep expertise in biomarker discovery, clinical assay development, and validation (including proficiency in designing and analyzing biomarker-driven clinical trials).
  • Strong experience in all aspects of pre-clinical oncology research.
  • Demonstrated leadership in translational medicine, with a track record of successful biomarker strategies leading to regulatory submissions, approvals, or high-impact publications.
  • Experience managing cross-functional and cross-institutional teams.
  • Excellent communication, reporting, and presentation skills.
  • Proven ability to thrive in dynamic, fast-paced environments and to mentor junior scientists and project teams.
  • Strong publication record and/or regulatory contributions in oncology clinical development.
  • Mandarin language proficiency is preferred but not required.
  • Education: PhD or MD/PhD in a relevant scientific discipline.
  • Travel: Not required
Responsibilities
  • Lead global clinical biomarker strategy for solid tumor oncology, in partnership with cross-functional teams, ensuring effective design and implementation of biomarker and companion diagnostic initiatives throughout the drug development continuum.
  • Oversee biomarker assay development and validation, including scientific input on assay design, proficiency testing, and analytical/clinical validation, ensuring readiness for regulatory and clinical decision points.
  • Direct the comprehensive analysis and interpretation of biomarker data to inform go/no-go decisions and trial advancement.
  • Effectively communicate with internal and external stakeholders, translating biomarker data into tangible insights and strategy recommendations.
  • Serve as scientific leader and subject matter expert, actively contributing to scientific discussions, program strategy, and the advancement of clinical stage projects.
  • Drive and manage external partnerships with academic institutions, CROs, and industry partners to enhance biomarker discovery and development efforts.
  • Contribute to regulatory submissions related to biomarker strategies and companion diagnostics.
  • Champion biomarker-related publications, driving thought leadership and innovation in oncology drug development.
Desired Qualifications
  • Mandarin language proficiency is preferred but not required

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA sales reached $3.9B in 2025, growing 49% year-over-year.
  • TEVIMBRA plus ZIIHERA shows extended survival versus trastuzumab in gastric cancer.
  • Three solid tumor programs advancing to late-stage trials with 60+ abstracts.

What critics are saying

  • BRUKINSA represents 73% of revenue; market share loss to competitors accelerates decline.
  • BEQALZI conditional approval requires CELESTIAL-RRMCL Phase 3 trial success by 2027.
  • Generic ibrutinib competition by 2027-2028 forces BRUKINSA price cuts or market share loss.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL.
  • BEQALZI is first BCL2 inhibitor approved for relapsed/refractory mantle cell lymphoma.
  • Global GMP manufacturing network enables cost-efficient drug development across 45+ countries.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...